Effectiveness of Calcimimetics on Fractures in Dialysis Patients with Secondary Hyperparathyroidism: Meta-analysis of Randomized Trials

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2024 Mar 27

PMID 38536478

Authors

Takuya Wakamatsu

Suguru Yamamoto

Koji Matsuo

Masatomo Taniguchi

Takayuki Hamano

Masafumi Fukagawa

Junichiro James Kazama

Affiliations

Soon will be listed here.

Abstract

Introduction: This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT).

Material And Methods: A comprehensive literature search was conducted using PubMed, Embase, and Cochrane Library for articles published through December 9, 2023. The quality of each trial was evaluated using the Cochrane Collaboration tool. Meta-analysis was performed using a random-effects model, and effect measures across studies were synthesized. The risk ratio (RR) and 95% confidence interval (CI) were used to quantify the risk of fracture.

Results: We identified seven studies involving 6481 dialysis patients with SHPT. The administration of calcimimetics reduced fracture incidence compared to placebo or conventional treatment (RR: 0.50, 95% CI 0.29-0.88, p = 0.02). Calcimimetics demonstrated a low number needed to treat (NNT) to prevent an incident fracture (NNT: 47).

Conclusion: The use of calcimimetics offers a significant benefit in reducing the risk of fractures in patients undergoing dialysis with SHPT.

Citing Articles

Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis.

Komaba H, Imaizumi T, Hamano T, Fujii N, Abe M, Hanafusa N Kidney Int Rep. 2024; 9(10):2956-2969.

PMID: 39430172 PMC: 11489479. DOI: 10.1016/j.ekir.2024.07.008.

Rationale and Protocol of the ETERNITY-ITA Study: Use of Etelcalcetide for Preserving Vitamin K-Dependent Protein Activity-An Italian Study.

Fusaro M, Aghi A, Marino C, Mallamaci F, Plebani M, Zaninotto M J Clin Med. 2024; 13(19).

PMID: 39407947 PMC: 11477619. DOI: 10.3390/jcm13195888.

References

Wakasugi M, Kazama J, Taniguchi M, Wada A, Iseki K, Tsubakihara Y . Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab. 2013; 31(3):315-21. DOI: 10.1007/s00774-012-0411-z. View

Alem A, Sherrard D, Gillen D, Weiss N, Beresford S, Heckbert S . Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58(1):396-9. DOI: 10.1046/j.1523-1755.2000.00178.x. View

Coco M, Rush H . Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000; 36(6):1115-21. DOI: 10.1053/ajkd.2000.19812. View

Tentori F, McCullough K, Kilpatrick R, Bradbury B, Robinson B, Kerr P . High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2013; 85(1):166-73. PMC: 3910091. DOI: 10.1038/ki.2013.279. View

Tentori F, Wang M, Bieber B, Karaboyas A, Li Y, Jacobson S . Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2014; 10(1):98-109. PMC: 4284424. DOI: 10.2215/CJN.12941213. View

Block G, Kilpatrick R, Lowe K, Wang W, Danese M . CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol. 2013; 8(12):2132-40. PMC: 3848404. DOI: 10.2215/CJN.04260413. View

Jadoul M, Albert J, Akiba T, Akizawa T, Arab L, Bragg-Gresham J . Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006; 70(7):1358-66. DOI: 10.1038/sj.ki.5001754. View

Block G, Martin K, de Francisco A, Turner S, Avram M, Suranyi M . Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350(15):1516-25. DOI: 10.1056/NEJMoa031633. View

Diaz-Tocados J, Rodriguez-Ortiz M, Almaden Y, Pineda C, Martinez-Moreno J, Herencia C . Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int. 2019; 95(5):1064-1078. DOI: 10.1016/j.kint.2018.12.015. View

10.

Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T . Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. Kidney Int Rep. 2021; 6(11):2830-2839. PMC: 8589700. DOI: 10.1016/j.ekir.2021.08.020. View

11.

Block G, Bushinsky D, Cheng S, Cunningham J, Dehmel B, Drueke T . Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017; 317(2):156-164. DOI: 10.1001/jama.2016.19468. View

12.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

13.

Moe S, Abdalla S, Chertow G, Parfrey P, Block G, Correa-Rotter R . Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2014; 26(6):1466-75. PMC: 4446874. DOI: 10.1681/ASN.2014040414. View

14.

Kazama J, Koiwa F, Yokoyama K, Fukagawa M, Asano K, Honda D . First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties. Clin Pharmacokinet. 2022; 61(9):1271-1284. PMC: 9439990. DOI: 10.1007/s40262-022-01139-w. View

15.

Cunningham J, Danese M, Olson K, Klassen P, Chertow G . Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68(4):1793-800. DOI: 10.1111/j.1523-1755.2005.00596.x. View

16.

Block G, Chertow G, Sullivan J, Deng H, Mather O, Tomlin H . An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One. 2019; 14(3):e0213774. PMC: 6420005. DOI: 10.1371/journal.pone.0213774. View

17.

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe Y . Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. Clin J Am Soc Nephrol. 2023; 18(10):1300-1309. PMC: 10578632. DOI: 10.2215/CJN.0000000000000253. View

18.

Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F . A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). Kidney Int Rep. 2020; 5(12):2168-2177. PMC: 7710846. DOI: 10.1016/j.ekir.2020.09.010. View

19.

Yeung W, Palmer S, Strippoli G, Talbot B, Shah N, Hawley C . Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2023; 82(5):543-558. DOI: 10.1053/j.ajkd.2023.04.003. View

20.

Rudser K, de Boer I, Dooley A, Young B, Kestenbaum B . Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol. 2007; 18(8):2401-7. DOI: 10.1681/ASN.2007010022. View